For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > COLUMN
COLUMN
-
Maurer’s Healthcare Insight (141)
January 30, 2012
-
Maurer’s Healthcare Insight (140)
December 26, 2011
-
Maurer’s Healthcare Insight (139)
December 12, 2011
-
Maurer’s Healthcare Insight (138)
November 21, 2011
-
Maurer’s Healthcare Insight(137)
October 17, 2011
-
Maurer’s Healthcare Insight (136)
September 12, 2011
-
Maurer's Healthcare Insight (135)
August 15, 2011
-
Maurer's Healthcare Insight (134)
August 1, 2011
-
Maurer's Healthcare Insight (133)
July 11, 2011
-
Maurer's Healthcare Insight (132)
May 30, 2011
-
Maurer's Healthcare Insight (131)
April 18, 2011
-
Maurer's Healthcare Insight (130)
January 24, 2011
-
Maurer's Healthcare Insight (129)
January 3, 2011
-
Maurer's Healthcare Insight (128)
December 13, 2010
-
Maurer's Healthcare Insight (127)
November 29, 2010
-
Maurer's Healthcare Insight (126)
November 8, 2010
-
Maurer's Healthcare Insight (125)
October 25, 2010
-
Maurer's Healthcare Insight (124)
October 11, 2010
-
Maurer's Healthcare Insight (123)
July 12, 2010
-
Maurer's Healthcare Insight (122)
May 31, 2010
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…